Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment

Alanood S Almurshedi, 1,* Hessah A Aljunaidel, 2 Bushra Alquadeib, 1 Basmah N Aldosari, 1,* Iman M Alfaqiah, 1 Salma S Almarshidy, 1 Eram KD Eltahir, 1 Amany Z Mohamoud 1 1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2Drug Regulatory Affairs, Novart...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Almurshedi AS, Aljunaidel HA, Alquadeib B, Aldosari BN, Alfagih IM, Almarshidy SS, Eltahir EKD, Mohamoud AZ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	ciprofloxacin ncfb nlcs ncmps dpi aerosolization. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/10fb590a12374f4d960d04cf72568f43
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10fb590a12374f4d960d04cf72568f43
record_format	dspace
spelling	oai:doaj.org-article:10fb590a12374f4d960d04cf72568f432021-12-02T14:25:40ZDevelopment of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment1178-2013https://doaj.org/article/10fb590a12374f4d960d04cf72568f432021-03-01T00:00:00Zhttps://www.dovepress.com/development-of-inhalable-nanostructured-lipid-carriers-for-ciprofloxac-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Alanood S Almurshedi, 1,* Hessah A Aljunaidel, 2 Bushra Alquadeib, 1 Basmah N Aldosari, 1,* Iman M Alfaqiah, 1 Salma S Almarshidy, 1 Eram KD Eltahir, 1 Amany Z Mohamoud 1 1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2Drug Regulatory Affairs, Novartis, Riyadh, Saudi Arabia*These authors contributed equally to this workCorrespondence: Alanood S AlmurshediDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 58488, Riyadh, 11594, Saudi ArabiaTel +966 118055013Fax +966 114697507Email marshady@ksu.edu.saPurpose: Ciprofloxacin (CIP) has poor lung targeting after oral inhalation. This study developed optimized inhalable nanostructured lipid carriers (NLCs) for CIP to enhance deposition and accumulation in deeper parts of the lungs for treatment of noncystic fibrosis bronchiectasis (NCFB).Methods: NLC formulations based on stearic acid and oleic acid were successfully prepared by hot homogenization and in vitro-characterized. CIP-NLCs were formulated into nanocomposite micro particles (NCMPs) for administration in dry powder inhalation (DPI) formulations by spray-drying (SD) using different ratios of chitosan (CH) as a carrier. DPI formulations were evaluated for drug content and in vitro deposition, and their mass median aerodynamic diameter (MMAD), fine particle fraction (FPF), fine particle dose (FPD), and emitted dose (ED) were determined.Results: The CIP-NLCs were in the nanometric size range (102.3 ± 4.6 nm), had a low polydispersity index (0.267 ± 0.12), and efficient CIP encapsulation (98.75% ± 0.048%), in addition to a spherical and smooth shape with superior antibacterial activity. The in vitro drug release profile of CIP from CIP-NLCs showed 80% release in 10 h. SD of CIP-NLCs with different ratios of CH generated NCMPs with good yield (> 65%). The NCMPs had a corrugated surface, but with increasing lipid:CH ratios, more spherical, smooth, and homogenous NCMPs were obtained. In addition, there was a significant change in the FPF with increasing lipid:CH ratios (P ˂  0.05). NCMP-1 (lipid:CH = 1:0.5) had the highest FPD (45.0 μg) and FPF (49.2%), while NCMP-3 (lipid:CH = 1:1.5) had the lowest FPF (37.4%). All NCMP powders had an MMAD in the optimum size range of 3.9– 5.1 μm.Conclusion: Novel inhalable CIP NCMP powders are a potential new approach to improved target ability and delivery of CIP for NCFB treatment.Keywords: ciprofloxacin, NCFB, NLCs, NCMPs, DPI, aerosolizationAlmurshedi ASAljunaidel HAAlquadeib BAldosari BNAlfagih IMAlmarshidy SSEltahir EKDMohamoud AZDove Medical Pressarticleciprofloxacinncfbnlcsncmpsdpiaerosolization.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 2405-2417 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ciprofloxacin ncfb nlcs ncmps dpi aerosolization. Medicine (General) R5-920
spellingShingle	ciprofloxacin ncfb nlcs ncmps dpi aerosolization. Medicine (General) R5-920 Almurshedi AS Aljunaidel HA Alquadeib B Aldosari BN Alfagih IM Almarshidy SS Eltahir EKD Mohamoud AZ Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
description	Alanood S Almurshedi, 1,* Hessah A Aljunaidel, 2 Bushra Alquadeib, 1 Basmah N Aldosari, 1,* Iman M Alfaqiah, 1 Salma S Almarshidy, 1 Eram KD Eltahir, 1 Amany Z Mohamoud 1 1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2Drug Regulatory Affairs, Novartis, Riyadh, Saudi Arabia*These authors contributed equally to this workCorrespondence: Alanood S AlmurshediDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 58488, Riyadh, 11594, Saudi ArabiaTel +966 118055013Fax +966 114697507Email marshady@ksu.edu.saPurpose: Ciprofloxacin (CIP) has poor lung targeting after oral inhalation. This study developed optimized inhalable nanostructured lipid carriers (NLCs) for CIP to enhance deposition and accumulation in deeper parts of the lungs for treatment of noncystic fibrosis bronchiectasis (NCFB).Methods: NLC formulations based on stearic acid and oleic acid were successfully prepared by hot homogenization and in vitro-characterized. CIP-NLCs were formulated into nanocomposite micro particles (NCMPs) for administration in dry powder inhalation (DPI) formulations by spray-drying (SD) using different ratios of chitosan (CH) as a carrier. DPI formulations were evaluated for drug content and in vitro deposition, and their mass median aerodynamic diameter (MMAD), fine particle fraction (FPF), fine particle dose (FPD), and emitted dose (ED) were determined.Results: The CIP-NLCs were in the nanometric size range (102.3 ± 4.6 nm), had a low polydispersity index (0.267 ± 0.12), and efficient CIP encapsulation (98.75% ± 0.048%), in addition to a spherical and smooth shape with superior antibacterial activity. The in vitro drug release profile of CIP from CIP-NLCs showed 80% release in 10 h. SD of CIP-NLCs with different ratios of CH generated NCMPs with good yield (> 65%). The NCMPs had a corrugated surface, but with increasing lipid:CH ratios, more spherical, smooth, and homogenous NCMPs were obtained. In addition, there was a significant change in the FPF with increasing lipid:CH ratios (P ˂  0.05). NCMP-1 (lipid:CH = 1:0.5) had the highest FPD (45.0 μg) and FPF (49.2%), while NCMP-3 (lipid:CH = 1:1.5) had the lowest FPF (37.4%). All NCMP powders had an MMAD in the optimum size range of 3.9– 5.1 μm.Conclusion: Novel inhalable CIP NCMP powders are a potential new approach to improved target ability and delivery of CIP for NCFB treatment.Keywords: ciprofloxacin, NCFB, NLCs, NCMPs, DPI, aerosolization
format	article
author	Almurshedi AS Aljunaidel HA Alquadeib B Aldosari BN Alfagih IM Almarshidy SS Eltahir EKD Mohamoud AZ
author_facet	Almurshedi AS Aljunaidel HA Alquadeib B Aldosari BN Alfagih IM Almarshidy SS Eltahir EKD Mohamoud AZ
author_sort	Almurshedi AS
title	Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
title_short	Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
title_full	Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
title_fullStr	Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
title_full_unstemmed	Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
title_sort	development of inhalable nanostructured lipid carriers for ciprofloxacin for noncystic fibrosis bronchiectasis treatment
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/10fb590a12374f4d960d04cf72568f43
work_keys_str_mv	AT almurshedias developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT aljunaidelha developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT alquadeibb developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT aldosaribn developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT alfagihim developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT almarshidyss developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT eltahirekd developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment AT mohamoudaz developmentofinhalablenanostructuredlipidcarriersforciprofloxacinfornoncysticfibrosisbronchiectasistreatment
_version_	1718391354053099520

Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment

Ejemplares similares